<DOC>
	<DOC>NCT01436474</DOC>
	<brief_summary>The objective of this proposal is to explore the potential of varenicline as a pharmacotherapeutic agent for opioid dependence and addiction.</brief_summary>
	<brief_title>Pilot Study of Varenicline to Treat Opioid Dependence</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Inclusion criteria Age&gt;=21 years Use of opioids at admission to PRC, with daily morphine equivalent dose&gt;=60mg Be able and willing to participate fully in all aspects of the study including one month followup after completion of PRC Ability to provide informed consent Exclusion criteria Currently using varenicline or other pharmacotherapy for nicotine dependence Currently pregnant, lactating, or likely to become pregnant during the trial and not willing to use an acceptable form of contraception; History of a major cardiovascular event in the past 6 months including unstable angina, acute myocardial infarction, stroke, or coronary angioplasty; Known varenicline allergy Use of any medication (e.g., methadone, Suboxone) as maintenance therapy for opiate addiction Identification of illicit drugs (e.g., marijuana, cocaine) on the baseline urine toxicology screen</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Varenicline</keyword>
	<keyword>Chantix</keyword>
	<keyword>Chronic Pain</keyword>
	<keyword>Opioid dependence</keyword>
</DOC>